Skip to main content

Table 1 Characteristics and quality of randomized control trials comparing bisphosphonates users and controls with regard to atrial fibrillation

From: Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

Author, year *Studies included in reports (Ref) Publication N †AF/BP users versus
AF/non-BP users
Age
(mean)
Study duration
(years)
Jadad
score
(1-5)
Black, 2007 NA Full text 7714 94/3862 versus
73/3852
73 3 4
Cummings, 2007 Black,
1996a (27)
Letter to the 2027 81/3236 versus 70.8 3 4
  Cummings, 1998a (28) editor 4432 71/3223 67.7 4.2 3
Lyles, 2007 NA Full text 2111 29/1054 versus
27/1057
74.5 5 4
Karam, 2007 Combination of trials b Letter to the editor 15066 Summary:
189/10018 versus
94/5048
73.5 NA NA
Papapoulous, 2008 Chesnut, 2005 (30)   2929   68.7 3 3
  Recker, 2004 (31) Abstract 2860 Summary: 67 3 4
  Reginster, 2006 (32)   1583 57/6830 versus
18/1924
66 2 4
  Eisman, 2008 (33)   1382   65.9 2 4
  1. *Randomized controlled trials included in letters to the editor and abstracts
  2. † Number of cases of AF in bisphosphonate users versus number of cases of AF in non-bisphosphonate users
  3. a Two Fracture Intervention Trials
  4. b Involved trials: Vertebral Efficacy with Risedronate Therapy Trial, the Bone Mineral Density Trial, the Risedronate
  5. 5 mg Daily Prevention Trial, the Glucocorticosteroid - Induced Osteoporosis Prevention and Treatment Trials and the
  6. Hip Intervention Program Trial
  7. Abbreviations: Ref, references; N, number of patients; AF, atrial fibrillation; BP, bisphosphonates; NA, not applicable